Ecuador Medical Director Accused Of Drug Irregularities

11 August 1996

The medical director of the Ecuadoran Social Security Institute, the IESS, Jean Rand, has been accused of "irregularities" in the acquisition of a group of drugs - six products in all - without observing the procedures laid down by law. The drugs were allegedly supplied to hospitals and patients, even though the drug companies had not been paid.

Vincente Atiaga, a spokesman for the IESS Council, noted that the drugs were for the treatment of arthritic conditions but claimed their acquisition for some $1.7 million did not have IESS approval. Raul Zapater, the director general of the IESS, is understood to have authorized the drugs' purchase, though on the understanding that the amount bought did not exceed $286,000. Mr Zapater has offered to resign but the Council has declined to accept his resignation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight